echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Hutchison China announces Sofantini SANET-ep mid-term analysis to reach main end point and terminate early

    Hutchison China announces Sofantini SANET-ep mid-term analysis to reach main end point and terminate early

    • Last Update: 2020-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Hutchison China Pharmaceutical Technology will hold a pre-ipo meeting with China's State Drug Administration (NMPA) to further discuss Sovantini's preparations for the application for new drug listing for the indications, and plans to present the results of the SANET-ep study at a recent academic conferenceSANET-ep is a Phase III clinical trial in China, with a group of patients with low- or moderate-level advanced non-pancreatic neuroendocrine tumors who are not currently effectively treatedIn the study, patients were randomly treated with a 2:1 ratio of 300 mg of sofantinib or placebo daily, with a 28-day treatment cycleThe main endpoints of the study were PFS, and secondary endpoints included objective mitigation rates (ORR), disease control rates (DCR), time to reach disease mitigation (TTR), duration of mitigation (DoR), total lifetime (OS), safety, and toleranceSofantinib (also known as HMPL-012) is a new type of oral antiangiogenic-immune escape kinase inhibitor that inhibits angiogenesis by inhibiting the endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), and sovantinini can also suppress the concentration of pyrient inflamed-1 receptors (CSF-1R) to promote the treatment of tumor-related macroblasts by CSF-1RBecause of this mechanism of action that inhibits both tumor angiogenesis and immune escape, Sofanitinib may be ideal for co-operation with other immunotherapy therapiesSofantini is currently conducting a number of proof-of-concept studies in the United States and China, and a number of late-stage clinical trials are under way in ChinaNote: The original text has a limitation
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.